Savarirayan, Ravi http://orcid.org/0000-0002-5105-8427
,
Tunkel, David E.
Sterni, Laura M.
Bober, Michael B.
Cho, Tae-Joon
Goldberg, Michael J.
Hoover-Fong, Julie
Irving, Melita
Kamps, Shawn E.
Mackenzie, William G.
Raggio, Cathleen
Spencer, Samantha A.
Bompadre, Viviana
White, Klane K.
Funding for this research was provided by:
BioMarin Pharmaceutical
Ascendis, Inc
Ultragenyx Pharmaceutical
QED Therapeutics
Article History
Received: 17 August 2020
Accepted: 5 January 2021
First Online: 14 January 2021
Ethics approval and consent to participate
: Not Applicable.
: Not Applicable.
: One or more of the authors (KKW, JHF, CR, MBB) has received funding from BioMarin Pharmaceuticals, SOBI, Medlife, OI Foundation. KKW has received benefits from BioMarin, Inc; Ultragenyx Pharmaceuticals; Alexion Pharmaceuticals, Inc; and QED Therapeutics. JHF has received benefits and payments from Therachon AG and Ascendis Pharma. WGM has received benefits from is BioMarin, Inc. and Little People of America. MBB has received benefits and payments from BioMarin, Inc. Therachon, QED Therapeutics, Ascendis Pharma. MJG has received payments from Guidepoint Global Network. CR has received payments from BioMarin Pharmaceutical, Ascendis Pharma, Alexion Pharmaceuticals. RS has received benefits and payments from pharmaceutical companies to support clinical trial work. SEK has received benefits from the Skeletal Dysplasia Management Consortium. All authors reaf and approved the final manuscript.